{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:33:04Z","timestamp":1784179984746,"version":"3.55.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"Importance<\/jats:title>Intranasal corticosteroids (INCs) remain the first-line treatment of chronic rhinosinusitis (CRS) in both adults and children, despite the lack of evidence regarding their efficacy in the pediatric population. Similarly, their effect on the sinonasal microbiome has not been well documented.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the clinical, immunological, and microbiological effects of 12 weeks of an INC in young children with CRS.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This open-label randomized clinical trial was performed in a pediatric allergy outpatient clinic in 2017 and 2018. Children aged 4 to 8 years with CRS diagnosed by a specialist were included. Data were analyzed from January 2022 to June 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized to receive intranasal mometasone in an atomizer for 12 weeks (1 application per nostril, once per day) and supplemental 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (INC group) or 3-mL NaCl, 0.9%, solution in a nasal nebulizer once a day for 12 weeks (control group).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Measures taken both before and after treatment included the Sinus and Nasal Quality of Life Survey (SN-5), a nasopharynx swab for microbiome analysis by next-generation sequencing methods, and nasal mucosa sampling for occurrence of innate lymphoid cells (ILCs).<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 66 children enrolled, 63 completed the study. The mean (SD) age of the cohort was 6.1 (1.3) years; 38 participants (60.3%) were male and 25 (39.7%) were female. The clinical improvement reflected by reduction in SN-5 score was significantly higher in the INC group compared with the control group (INC group score before and after treatment, 3.6 and 3.1, respectively; control group score before and after treatment, 3.4 and 3.8, respectively; mean between-group difference, \u22120.58; 95% CI, \u22121.31 to \u22120.19; P<\/jats:italic>\u2009=\u2009.009). The INC group had a greater increase in nasopharyngeal microbiome richness and larger decrease in nasal ILC3 abundance compared with the control group. A significant interaction was observed between change in microbiome richness and the INC intervention on the prediction of significant clinical improvement (odds ratio, 1.09; 95% CI, 1.01-1.19; P<\/jats:italic>\u2009=\u2009.03).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This randomized clinical trial demonstrated that treatment with an INC improved the quality of life of children with CRS and had a significant effect on increasing sinonasal biodiversity. Although further investigation is needed of the long-term efficacy and safety of INCs, these data may reinforce the recommendation of using INCs as a first-line treatment of CRS in children.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03011632<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2022.6172","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T16:01:10Z","timestamp":1677513670000},"page":"345","source":"Crossref","is-referenced-by-count":20,"title":["Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis"],"prefix":"10.1001","volume":"177","author":[{"given":"Marta","family":"Latek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"\u0141acwik","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Moli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"B\u0142au\u017c","sequence":"additional","affiliation":[{"name":"Cytometry Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Lach","sequence":"additional","affiliation":[{"name":"Biobank Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u0142a\u017cej","family":"Rychlik","sequence":"additional","affiliation":[{"name":"Cytometry Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Strapagiel","sequence":"additional","affiliation":[{"name":"Biobank Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Majak","sequence":"additional","affiliation":[{"name":"Audiology and Phoniatrics Clinic, Nofer Institute of Occupational Medicine, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Moli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Czech","sequence":"additional","affiliation":[{"name":"Department of Paediatric Otolaryngology, Audiology and Phoniatrics, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Seweryn","sequence":"additional","affiliation":[{"name":"Biobank Lab, Faculty of Biology and Environmental Protection and Centre for Data Analysis, Modeling and Computational Sciences (CAMiNO), University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Pa\u0142czy\u0144ski","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Jan Kochanowski University, Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Majak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonology, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"poi220100r1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/Rhin","article-title":"Executive summary of EPOS 2020 including integrated care pathways.","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"3","key":"poi220100r2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.v11.3","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021.","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"poi220100r3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1710-1492-4-3-125","article-title":"Evaluating the safety of intranasal steroids in the treatment of allergic rhinitis.","volume":"4","author":"Sheth","year":"2008","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"poi220100r4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0194599820931454","article-title":"Intranasal corticosteroid therapy: systematic review and meta-analysis of reported safety and adverse effects in children.","volume":"163","author":"Donaldson","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"poi220100r5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/0145561320967727","article-title":"A scholarly review of the safety and efficacy of intranasal corticosteroids preparations in the treatment of chronic rhinosinusitis.","volume":"100","author":"Macias-Valle","year":"2021","journal-title":"Ear Nose Throat J"},{"issue":"3","key":"poi220100r6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.wjorl.2018.08.004","article-title":"The microbiome and chronic rhinosinusitis.","volume":"4","author":"Sivasubramaniam","year":"2018","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"issue":"3","key":"poi220100r7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1071\/MA16051","article-title":"Chronic rhinosinusitis: a microbiome in dysbiosis and the search for alternative treatment options.","volume":"37","author":"Bordin","year":"2016","journal-title":"Microbiol Aust"},{"issue":"5","key":"poi220100r8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.jaci.2022.02.022","article-title":"Unraveling the role of the microbiome in chronic rhinosinusitis.","volume":"149","author":"Psaltis","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"poi220100r9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40168-017-0266-6","article-title":"Compositionally and functionally distinct sinus microbiota in chronic rhinosinusitis patients have immunological and clinically divergent consequences.","volume":"5","author":"Cope","year":"2017","journal-title":"Microbiome"},{"key":"poi220100r10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fcimb.2018.00057","article-title":"Chronic rhinosinusitis: potential role of microbial dysbiosis and recommendations for sampling sites.","volume":"8","author":"Copeland","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"poi220100r11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11882-019-0861-7","article-title":"Contributions of innate lymphoid cells in chronic rhinosinusitis.","volume":"19","author":"Luong","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"poi220100r12","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.jaci.2021.03.015","article-title":"Roles of innate lymphoid cells (ILCs) in allergic diseases: the 10-year anniversary for ILC2s.","volume":"147","author":"Bartemes","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"poi220100r13","first-page":"1","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2012.","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol Suppl"},{"issue":"10","key":"poi220100r14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1164\/rccm.201210-1913OC","article-title":"Comparison of the respiratory microbiome in healthy nonsmokers and smokers.","volume":"187","author":"Morris","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"poi220100r15","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1038\/s41467-019-13751-9","article-title":"Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients.","volume":"10","author":"Michalovich","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"poi220100r16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/all.v77.1","article-title":"House dust mite sensitization and frequent antibiotic courses may suppress remission of rhinosinusitis and asthma symptoms in young children.","volume":"77","author":"Molinska","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"poi220100r17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1067\/mhn.2003.41","article-title":"Quality of life for children with persistent sinonasal symptoms.","volume":"128","author":"Kay","year":"2003","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"poi220100r18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/jcm11030507","article-title":"The long-term effects of 12-week intranasal steroid therapy on adenoid size, its mucus coverage and otitis media with effusion: a cohort study in preschool children.","volume":"11","author":"Zwierz","year":"2022","journal-title":"J Clin Med"},{"key":"poi220100r19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/JAA.S321332","article-title":"Intranasal corticosteroids: topical potency, systemic activity and therapeutic index.","volume":"14","author":"Daley-Yates","year":"2021","journal-title":"J Asthma Allergy"},{"key":"poi220100r20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ijporl.2018.06.010","article-title":"The Sinus and Nasal Quality of Life Survey (SN-5) in the management of pediatric chronic rhinosinusitis: a systematic review and meta-analysis.","volume":"111","author":"Ni","year":"2018","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"5","key":"poi220100r21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00774-010-0255-3","article-title":"Lack of bone metabolism side effects after 3 years of nasal topical steroids in children with allergic rhinitis.","volume":"29","author":"Emin","year":"2011","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"poi220100r22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/alr.v10.4","article-title":"Association of the sinonasal bacterial microbiome with clinical outcomes in chronic rhinosinusitis: a systematic review.","volume":"10","author":"Wang","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"poi220100r23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/hn.2003.v128.amhn0312811","article-title":"Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology.","volume":"129","author":"Benninger","year":"2003","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"poi220100r24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1183\/09031936.00074712","article-title":"Climate change, extreme weather events, air pollution and respiratory health in Europe.","volume":"42","author":"De Sario","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"poi220100r25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MOO.0b013e32832ad3c0","article-title":"The role of allergy in rhinosinusitis.","volume":"17","author":"Pant","year":"2009","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"3","key":"poi220100r26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/alr.2014.4.issue-3","article-title":"Genetic variations in taste receptors are associated with chronic rhinosinusitis: a replication study.","volume":"4","author":"Mfuna Endam","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"poi220100r27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000499875","article-title":"Single nucleotide polymorphisms in chemosensory pathway genes GNB3, TAS2R19, and TAS2R38 are associated with chronic rhinosinusitis.","volume":"180","author":"Purnell","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"poi220100r28","doi-asserted-by":"publisher","DOI":"10.1002\/alr.2018.8.issue-8","article-title":"The effect of medical treatments on the bacterial microbiome in patients with chronic rhinosinusitis: a pilot study.","author":"Jain","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"issue":"9","key":"poi220100r29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/alr.v11.9","article-title":"Sinonasal and gastrointestinal bacterial composition and abundance are stable after 1 week of once-daily oral antibiotic treatment for chronic rhinosinusitis.","volume":"11","author":"Siu","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"poi220100r30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.595555","article-title":"Antibiotic treatment for chronic rhinosinusitis: prescription patterns and associations with patient outcome and the sinus microbiota.","volume":"11","author":"Lux","year":"2020","journal-title":"Front Microbiol"},{"issue":"6","key":"poi220100r31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4193\/Rhin","article-title":"The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial.","volume":"58","author":"Cherian","year":"2020","journal-title":"Rhinology"},{"issue":"3","key":"poi220100r32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jaad.2016.04.066","article-title":"Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis.","volume":"75","author":"Gonzalez","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"poi220100r33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1164\/rccm.202102-0289OC","article-title":"Effects of inhaled corticosteroid\/long-acting \u00df2-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease: a randomized controlled clinical trial (DISARM).","volume":"204","author":"Leitao Filho","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2801803\/jamapediatrics_latek_2023_oi_220100_1680182420.92642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T15:09:17Z","timestamp":1680534557000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2801803"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2022.6172","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}